Hefei Enrit Pharmaceutical Co., Ltd.

1. Primary objective: To evaluate the safety and tolerability of a single injection of different doses of HY-022619 for injection in healthy subjects. 2. Secondary objectives 1) To evaluate the pharmacokinetic (PK) characteristics of a single injection of different doses of HY-022619 for injection in healthy subjects; 2) To evaluate the pharmacodynamic (PD) characteristics of a single injection of different doses of HY-022619 for injection in healthy subjects; 3) To evaluate the differences in pharmacokinetic/pharmacodynamic characteristics after a single intravenous injection of HY-022619 and a single oral administration of ticagrelor tablets in healthy subjects. Exploratory objective: To evaluate the PK/PD correlation after a single administration of different doses of HY-022619 for injection in healthy subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of diphenhydramine citrate ibuprofen tablets (specifications: 38mg/200mg/tablet) produced by Hefei Enrui Pharmaceutical Co., Ltd. and diphenhydramine citrate ibuprofen tablets (trade name: ADVIL PM®, specifications: 38mg/200mg/tablet) held by the licensee Glaxosmithkline Consumer Healthcare Holdings US LLC after single oral administration under fasting/postprandial conditions in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and reference preparation of diphenhydramine citrate ibuprofen tablets after single oral administration in healthy Chinese subjects.

Main purpose of the study: According to the relevant provisions of bioequivalence tests, the licensee of Rivaroxaban orodisintegrating tablets (trade name: Xarelto®, specification: 15 mg) was selected as the reference preparation, and the test preparation Rivaroxaban orodisintegrating tablets (specification: 15 mg) produced and provided by Hefei Enrui Pharmaceutical Co., Ltd. were subjected to human bioequivalence tests on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation Rivaroxaban orodisintegrating tablets (specification: 15 mg) and the reference preparation Rivaroxaban orodisintegrating tablets (trade name: Xarelto®, specification: 15 mg) by healthy volunteers.